Progression of liver fibrosis in HIV/hepatitis C virus‐coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline

• Published in: HIV medicine 2014-04, Vol.15 (4), p.203-212
• Main Authors: Sanmartín, R, Tor, J, Sanvisens, A, López, JJ, Jou, A, Muga, R, Ojanguren, I, Barluenga, E, Videla, S, Planas, R, Clotet, B, Tural, C
• Format: Article
• Language: English
• Subjects: Adult; Age Factors; Antiretroviral Therapy, Highly Active; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Coinfection - drug therapy; Disease Progression; Female; Hepatitis C - complications; Hepatitis C - drug therapy; HIV Infections - complications; HIV Infections - drug therapy; HIV/HCV coinfection; Humans; Interferons - administration & dosage; Interferons - therapeutic use; liver biopsy; Liver Cirrhosis - mortality; Liver Cirrhosis - pathology; liver fibrosis; Male; Prospective Studies; Retrospective Studies; Ribavirin - administration & dosage; Ribavirin - therapeutic use; Risk Factors; transient elastometry
• ISSN: 1464-2662; 1468-1293
• DOI: 10.1111/hiv.12105

Objectives The aim of the study was to assess the progression of liver fibrosis in HIV/hepatitis C virus (HCV)‐coinfected patients with no or mild‐to‐moderate fibrosis (stages F0−F2). Methods Liver fibrosis was reassessed by transient elastometry (TE) between January 2009 and November 2011 in HIV/HCV‐coinfected patients with stage F0−F2 fibrosis in a liver biopsy performed between January 1997 and December 2007. Patients with liver stiffness at the end of follow‐up